Циклопирокс: клинический опыт и современные тенденции в топической терапии онихомикоза

________________________________________________

1. Nenoff P, Ginter-Hanselmayer G, Tietz HJ. Fungal nail infections – an update: Part 1 – Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt 2012; 63: 30–8.
2. Havlickova A, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008; 51 (4): 2–15.
3. Watanabe S, Harada T, Hiruma M et al. Epidemiological survey of foot diseases in Japan: Results of 30 000 foot checks by dermatologists. J Dermatol 2010; 37: 397–406.
4. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236: 1–26.
5. Tosti A, Piraccini BM. Biology of nails and nail disorders. In: Wolff K, Goldsmith LA, Katz SI et al, editors. Fitzpatrick's Dermatology In General Medicine. McGraw-Hill Companies Inc., 2007; p. 778–94.
6. Matsuda Y, Sugiura K, Hashimoto T et al. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis. PLoS ONE 2016; 11 (7): e0159661. DOI: 10.1371/journal.pone.0159661
7. CLogP (Daylight Chemical Information Systems). http://www.daylight.com/daycgi/clogp
8. Hansen S, Selzer D, Schaefer UF, Kasting GB. An extended database of keratin binding. J Pharm Sci 2011; 100: 1712–26.
9. Tatsumi Y, Yokoo M, Senda H, Kakehi K. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother 2002; 46 (12): 3797–801.
10. Thatai P, Tiwary AK, Sapra B. Progressive development in experimental models of transungual drug delivery of anti-fungal agents. Int J Cosmet Sci 2015: 1–12.
11. Jo Siu WJ, Tatsumi Y, Senda H et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother 2013; 57: 1610–6.
12. Monti D, Herranz U, Dal Bo L, Subissi A. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects. J Eur Acad Dermatol Venereol 2013; 27 (2): 153–8.
13. Elewski BE, Ghannoum MA, Mayser P et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mildto-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label activecontrolled designs. J Eur Acad Dermatol Venereol 2013; 27: 287–94.
14. Täuber A, Müller-Goymann CC. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model. Mol Pharm 2014; 11 (7): 1991–6.
15. Baran R, de Berker D, Holzberg M, Thomas L. Diseases of the nails and their management. 4th edn. Oxford: Wiley-Blackwell, 2012.
16. Baran R, Tosti A, Hartmane I et al. An innovative watersoluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23 (7): 773–81.
17. Shen T, Huang S. Repositioning the Old Fungicide Ciclopirox for New Medical Uses. Cur Pharm Des 2016; 22 (28): 4443–50.
18. Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004; 43 (Suppl. 1): 3–8.
19. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43 (Suppl. 4): 57–69.
20. Leem SH, Park JE, Kim IS et al. The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells 2003; 15 (1): 55–61.
21. Niewerth M, Kunze D, Seibold M et al. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47 (6): 1805–17.
22. Subissi A, Monti D, Togni G. Ciclopirox recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010; 70: 2133–52.
23. Sigle HC, Thewes S, Niewerth M et al. Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. J Antimicrob Chemother 2005; 55: 663–73.
24. Eberhard Y, McDermott SP, Wang X et al. Chelation of intracellular iron with the antifungal agent ciclopiroxolamine induces cell death in leukemia and myeloma cells. Blood 2009; 114: 3064–73.
25. Niewerth M, Kunze D, Seibold M et al. Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors. Antimicrob Agents Chemother 2003; 47 (6): 1805–17.
26. Ghelardi E, Celandroni F, Gueye SA et al. Potential of Ergosterol Synthesis Inhibitors To Cause Resistance or Cross-Resistance in Trichophyton rubrum. Antimicrob Agents Chemother 2014; 58 (5): 2825–9.
27. Ploysangam T, Lucky AW. Childhood white superficial onychomycosis caused by Trichophyton rubrum: Report of seven cases and review of the literature. J Am Acad Dermatol 1997; 36: 29–32.
28. Rodríguez-Pazos L, Pereiro-Ferreirós MM, Pereiro MJr et al. Onychomycosis observed in children over a 20-year period. Mycoses 2011; 54 (5): 450–3.
29. Friedlander SF, Chan YC, Chan YH. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol 2013; 30 (3): 316–22.

________________________________________________

E.I.Kasihina*
Central State Medical Academy оf Administration of the President of the Russian Federation. 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a
*kasprof@bk.ru